Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Depreciation: 2022-2025

Historic Accumulated Depreciation for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $4.4 million.

  • Taysha Gene Therapies' Accumulated Depreciation rose 12.03% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 12.03%. This contributed to the annual value of $3.6 million for FY2024, which is 20.31% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Accumulated Depreciation is $4.4 million, which was up 6.98% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Accumulated Depreciation peaked at $4.4 million during Q3 2025, and registered a low of $754,000 during Q1 2022.
  • Moreover, its 3-year median value for Accumulated Depreciation was $3.6 million (2024), whereas its average is $3.3 million.
  • Data for Taysha Gene Therapies' Accumulated Depreciation shows a peak YoY spiked of 161.67% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Accumulated Depreciation (Quarterly) stood at $1.6 million in 2022, then skyrocketed by 81.43% to $3.0 million in 2023, then climbed by 20.31% to $3.6 million in 2024, then climbed by 12.03% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.1 million for Q2 2025, and $3.8 million during Q1 2025.